FGF2抗体;FGF2 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using FGF2 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

Fibroblast Growth Factor 2 (FGF2), also known as basic FGF, is a multifunctional protein belonging to the FGF family, which regulates cellular processes such as proliferation, differentiation, angiogenesis, and tissue repair. FGF2 antibodies are essential tools for detecting, quantifying, and functionally characterizing this growth factor in both research and clinical contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assays (ELISA) to study FGF2 expression patterns in development, homeostasis, and disease.

FGF2 exists in multiple isoforms (e.g., 18 kDa cytoplasmic and higher molecular weight nuclear forms) due to alternative translation initiation, and specific antibodies are designed to target distinct epitopes or post-translational modifications. This specificity allows researchers to investigate isoform-specific roles in pathologies, including cancer, fibrosis, and cardiovascular disorders. For instance, FGF2 overexpression is linked to tumor angiogenesis and metastasis, making its antibodies valuable in oncology research.

Therapeutic FGF2-neutralizing antibodies are also explored to block aberrant FGF signaling in diseases. Commercially available FGF2 antibodies vary by clonality (monoclonal/polyclonal), species reactivity, and applications, requiring validation for experimental reproducibility. Understanding FGF2’s interaction with receptors (FGFRs) and heparan sulfate proteoglycans further underscores the importance of high-affinity antibodies in elucidating its complex signaling networks. Overall, FGF2 antibodies remain indispensable for advancing both basic research and targeted therapies.